<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02464319</url>
  </required_header>
  <id_info>
    <org_study_id>hrIL-2-SS1</org_study_id>
    <nct_id>NCT02464319</nct_id>
  </id_info>
  <brief_title>A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome</brief_title>
  <official_title>Safety and Efficiency Study of Low-dose IL-2 Treatment in Primary Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing ShuangLu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Sjögren's Syndrome (pSS) is an autoimmune disorder characterized by
      keratoconjunctivitis sicca and xerostomia. In addition, various extraglandular manifestations
      may develop. Several immunomodulating agents have been attempted in the treatment of pSS
      without achieving satisfactory results. Currently, there is no approved systemic treatment
      for pSS. Dysfunction of regulatory T (Treg) cells has been detected in diverse autoimmune
      diseases, which can be promoted by interleukin-2 (IL-2). The investigators hypothesized that
      low-dose IL-2 could be a novel therapy in active pSS patients. This clinical study will test
      the efficacy and safety of low dose IL-2 treatment in pSS. The investigators perform a
      single-centre, double-blind pilot trial with hrIL-2 in pSS. The investigators evaluate the
      effectiveness and safeness of low-dose hrIL-2 for primary Sjögren's Syndrome by randomized
      controlled study (hrIL-2 (N = 30) versus placebo group (N = 30)).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each pSS patients (n=60) with Scores&gt;=6 on ESSDAI received low-dose IL-2 or placebo (active
      group: placebo group =1:1, 1 million units every other day subcutaneously (HrIL-2 1X 106, ip,
      Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3 cycles. The
      end points were safety, clinical and immunologic response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2015</start_date>
  <completion_date type="Actual">August 31, 2017</completion_date>
  <primary_completion_date type="Actual">March 31, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Examination of the therapeutic effects (improvement in ESSDAI) of low dose IL-2 in patients with primary Sjögren's Syndrome</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological Responses</measure>
    <time_frame>0,12,24weeks</time_frame>
    <description>Analysis regulatory CD4+ T (Treg) cells , interleukin 17 (IL-17)-producing helper T (Th17) cells and follicular helper T (Tfh) cells before and during IL-2 treatment. P values below 0.05 are considered statistically significant in this study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Primary Sjögren's Syndrome</condition>
  <arm_group>
    <arm_group_label>Experimental: hrIL-2 active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention：Add hrIL-2 according to the protocol to original treatment. HrIL-2 active: 1 million U doses of human recombinant interleukin-2 s.c. injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: hrIL-2 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 million U doses of placebo s.c. injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hrIL-2 active</intervention_name>
    <description>1 million U doses of human recombinant interleukin-2 s.c. injection active group: placebo group =1:1</description>
    <arm_group_label>Experimental: hrIL-2 active</arm_group_label>
    <other_name>Human recombinant IL-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hrIL-2 placebo</intervention_name>
    <description>1 million U doses of placebo s.c. injection active group: placebo group =1:1</description>
    <arm_group_label>Placebo Comparator: hrIL-2 placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of a primary Sjögren´s Syndrome

          -  ESSDAI score ≥ 6

          -  Liver values above 1,5 ULN

          -  Stable low dose systemic use of Glucocorticoids（&lt;=7.5mg） in the last 4 weeks before
             begin with Study medication

        Exclusion Criteria:

          -  Secondary Sjögren's Syndrome

          -  Pre-treatment with Cyclosporine A

          -  Receiving cyclosphosphamide, corticosteroid bolus with dose over 1 mg/kg, rituximab,
             belimumab, other immunosuppressives

          -  Infection

          -  Neoplasia

          -  Relevant cardiac, pulmonary, neurologic or psychiatric disease

          -  Life-Vaccination within 4 weeks before begin with study medication

          -  Pregnant or breast-feeding

          -  Weight under 45kg or more than 80kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhanguo Li, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Institute of Rheumatology and Immunology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Rheumatology and Immunology, Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2015</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Zhanguo Li</investigator_full_name>
    <investigator_title>Chief of Department of Rheumatology and Immunology,Peking University People's Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

